ERBB2 and breast cancer: HER2-positive breast cancer also provides a clear example of the relationship between client driver-protein dependence on Hsp90 and potential clinical efficacy [48], since this receptor is highly sensitive to Hsp90 chaperone inhibition and these tumors are exquisitely dependent on HER2-driven signaling for growth and survival.